Cardiomyopathy is a cardiovascular disease that makes it difficult for the heart to pump blood to the rest of the body. Patients with atrial fibrillation (AF) are at a higher risk of ischemic and nonischemic cardiomyopathy, which may lead to congestive heart failure (CHF). This study aims to investigate the treatment strategies and outcomes of antithrombotic and CHF therapies for patients with AF.

This prospective study included a total of 52,014 patients with AF, of which 11,738 patients with newly diagnosed AF and at least 1 investigator-determined stroke risk factor were included. The primary outcomes of the study were event rates per 100 person-years as estimated by the Poisson model and Cox hazard ratios.

Of 11,738 patients with CHF, 4,717 (40.2%) had ischemic cardiomyopathy (ICM) and 7,021 (59.8%) had non ischemic cardiomyopathy. The findings suggested that the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β blockers was higher in the ICM group, as compared with the NICM group. The rate of all-cause and cardiovascular mortality was significantly higher in the ICM group (all-cause: 10.2 vs. 7.0 per 100 person-years, cardiovascular: 5.1 vs. 2.9) than in the NICM group.

The research concluded that patients with ICM received angiotensin-converting enzyme inhibitors and β blockers more frequently than those in the NICM group. Further, the risk of all-cause and cardiovascular mortality was higher in the ICM group.